Indeed, mice with group 3 medulloblastoma showed a significant survival benefit after treatment with anti-programmed death 1 (anti-PD1) antibodies compared to untreated mice, whereas mice with SHH-activated medulloblastoma did not show a significant response to the same therapy. This evidence concerns the gene SHH and medulloblastoma.